FY2007
Financial Results
Presentation

May 14, 2008

Aquavan® (fospropofol disodium)
Advancing *hhc* in Minimal to Moderate Sedation Market

Advisory Committee (held on May 7)

- FDA Advisory Committee (ALSDAC) voted **in favor** of approval of Aquavan® for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or

Contribution of MGI in Medium to Long Term



Project	Target indication		
Aloxi® oral	Chemotherapy-induced nausea and vomiting (CINV)	Launched	
	Post-operative nausea and vomiting (PONV)	Approved in Feb. 2008	
	Chemotherapy-induced nausea and vomiting (CINV)	Filed	U.S., Canada
	Myelodysplastic syndromes (MDS)		
	Acute myeloid leukemia (AML)	Phase III	
	MDS survival		
	Malignant glioma/glioblastoma at time of initial surgery		
	Ovarian cancer		
Salagen®	Symptoms for radiation-induced dry mouth in head and neck cancer patients	Launched	(Eisai markets in U.S. outlicensed outside U.S.)
	Sedative agent for brief therapeutic and diagnostic procedures		
	Cervical dysplasia		
Saforis™	Oral mucositis	Phase III	Worldwide
	Idiopathic thrombocytopenic purpura (ITP)		
	Hepatitis-C-related thrombocytopenia		
	Chemotherapy-induced thrombocytopenia (CIT)		
ZYC300	Hormone refractory prostate cancer Solid tumors	Phase I/II	Worldwide
GPI 21016 rc 0.0036 T 3xi	Cancer therapy, radiotherapy sensitizer		
	Chemotherapy-induced neuropathy		

Financial reporting based on current accounting standards

I. FY2007 Financial Results

	FY2006			FY2007		
	Results	%	Results (GAB.6	Results (Adjusted)	%	
	674.1			**734.3**	100.0	
	109.3			**113.3**	15.4	
	564.8			**620.9**	84.6	
	108.3			**137.8**	18.8	
	351.2			**372.3**	50.7	
	105.3			**110.8**	15.1	
Ordinary Income	110.5	16.4	**18.9**	**111.9**	15.2	101
Net Income	70.6	10.5	**(17.0)**	**70.7**	9.6	100

Consolidated Cash Income

Cash Income = Net Income/Loss + Amortization of Tangible/Intangible Assets
+ IPR&D Expenses + Amortization of Goodwill + Impairment Loss

(billion yen, %)

	FY2006	FY2007		
	Results	Results	YOY	Increase (Decrease)
a. Net Income/Loss	70.6	**(17.0)**	-	(87.6)
b. Amortization of Tangible and Intangible Assets	26.6	**28.5**	107	1.9
c. Amortization of Intangible Assets due to Acquisitions*	-	**5.9**	-	5.9
d. In Process R&D Expenses*	-	**88.0**	-	88.0
e. Amortization of Goodwill	0.2	**0.0**	5	(0.2)
f. Impairment Loss	0.2	**0.1**	30	(0.1)
g. Cash Income (a+b+c+d+e+f)	97.6	**105.5**	108	7.9
h. Cash EPS (yen)	343	**371**	108	28
I. Dividend per Share (yen)	120	**130**	108	10

*Acquisition of MGI Pharma, Inc. and Morphotek, Inc.

Products	Area	FY2006	FY2007	
		Results	Results	YOY (%)
Aricept® Alzheimer's Disease Treatment	Japan	49.7	**62.3**	125
	U.S.	162.2	**186.9**	115
	$ million	*1,386*	***1,635***	*118*
	Europe	34.5	**33.3**	96
	Asia	6.6	**8.5**	130
	Total	252.9	**291.0**	115
AcipHex®/ *Pariet*® Proton Pomp Inhibitor Anti-ulcer Agent	Japan	30.7	**37.1**	121
	U.S.	126.9	**124.7**	98
	$ million	*1,084*	***1,091***	*101*
	Europe	12.1	**8.6**	71
	Asia	4.6	**5.5**	119
	Total	174.3	**175.9**	101

Sales to Customers by Geographic Area

(billion yen, %)

	FY2006		FY2007			
	Results	%	Results	%	YOY(%)	Increase (Decrease)
Japan	292.2	43.3	**312.7**	42.6	107	20.4
North America	303.4	45.0	**339.4**	46.2	112	36.0
Europe	54.8	8.1	**54.4**	7.4	99	(0.4)
Asia & others	23.7	3.5	**27.8**	3.8	117	4.1
Overseas	381.9	56.7	**421.6**	57.4	110	39.7
Total	674.1	100.0	**734.3**	100.0	109	60.2

	FY2006		FY2007			
	Results	%	Results	%	YOY (%)	Increase (Decrease)
Japan	72.8	66.4	**80.5**	383.0	111	7.7
North America*	28.8	26.2				

Operating Income by Geographic Area (Adjusted)

(billion yen, %)

	FY2006		FY2007			
	Results	%	Results	%	YOY (%)	Increase (Decrease)
Japan	72.8	66.4	**80.5**	70.6	111	7.7
North America*	28.8	26.2	**26.2**	22.9	91	**(2.6)
Europe	4.1	3.7	**1.8**	1.6	44	(2.3)
Asia & others	4.0	3.7	**5.6**	4.9	140	1.6
Overseas	36.8	33.6	**33.6**	29.4	91	(3.3)
Sub Total	109.6	100.0	**114.1**	100.0	104	4.4
Elimination/ Corporate	(4.4)		**(3.3)**		-	1.1
Total	105.3		**110.8**		105	5.5

* : Consolidated operating income generated by subsidiaries in North America

**: Mainly due to change of royalty ratio to the parent company and accounting transaction associated with business combination with MGI PHARMA

	FY2006		FY2007			
	Results	%	Results	%	YOY (%)	Change
Net Revenue	2,612	100.0	**2,911**	100.0	111	300
Aricept®	1,386	53.1	**1,635**	56.2	118	249
AcipHex®	1,084	41.5	**1,091**	37.5	101	7
Fragmin®	66	2.5	**74**	2.5	112	8
4 Cancer Products (ONTAK® and others)	10	0.4	**54**	1.9	523	44
Operating Income						

Consolidated Cash Flow

(billion yen)

	Cash Flow from Operating Activities		Capital Expenditure		Free Cash Flow		Cash Income	
	Results	Increase (Decrease)	Results	Increase (Decrease)	Results	Increase (Decrease)	Results	Increase (Decrease)
FY2003	72.7	15.1	23.8	(2.7)	48.9	17.8	68.6	9.6
FY2004	49.2	(23.5)	38.7	14.9	10.5	(38.4)	77.9	9.3
FY2005	87.1	37.9	43.5	4.8	43.6	33.1	88.6	10.8
FY2006	81.2	(5.9)	52.5	9.1	28.6	(14.9)	97.6	9.0
FY2007	**73.2**	**(7.9)**	**489.1**	***436.6**	**(415.9)**	**(444.5)**	**105.5**	**7.9**

*: Including 435.5 billion yen acquisition costs of MGI PHARMA, Inc. and Morphotek Inc.

II. R&D

Progress of High-Priority Corporate Projects

Corporate programs that will ensure product launches in the Dramatic Leap Plan

- E7389 (eribulin mesylate, microtubule growth suppressor)
  - 3rd line breast cancer
    - U.S. FDA agreed Eisai may submit NDA for late-stage 3rd line breast indication based on the 211 study and the 305 study (E7389 vs. drug therapy selected by doctor)
    - In Japan, J-NDA is to be submitted based on results from Study 305 (international study) and Study 221 (Japan Phase II study).
    - Submission target: Simultaneous NDA/MAA submissions in Japan, U.S. and Europe in FY2009
- E5564 (eritoran tetrasodium, TLR4 antagonist)
  - Severe sepsis
    - A multinational Phase III “ACCESS” study ongoing in 23 countries including Japan, Europe, U.S. and Asia
    - Smooth patient enrollment by adding and activating sites
    - Submission target: Simultaneous NDA/MAA submissions in Japan, U.S., Europe and Asia in FY2009
- E2007 (perampanel, AMPA receptor antagonist)
  - Neuropathic pain
    - Phase II studies ongoing for painful diabetic neuropathy (Study 227) and postherpetic neuralgia (Study 218). Enrollment for Study 227 was completed in January 2008 and database lock to be completed in 2Q FY2008
    - Submission target: NDA/MAA submissions in FY2010
  - Epilepsy
    - Demonstrated good tolerability and efficacy trends in reduction of seizure frequency that is similar to other AEDs

Progress of Potential First-in-class/Best-in-class drugs

Focusing on growing markets including oncology and Alzheimer's disease

- E2012 (gamma-secretase modulator)
  - Alzheimer's disease
    - Received a notification from the U.S. FDA that Eisai may proceed with Phase I study for E2012 on April 2, 2008
    - Phase I study to resume in 1Q FY2008
    - Figure out the proof of pharmacology and determine effective dose by evaluating beta amyloid as pharmacological biomarkers in Phase I study and consider possible options including utilizing adaptive design to expedite Phase II and III
    - Submission target: Simultaneous NDA/MAA submissions in Japan, U.S. and Europe in FY2011
- E5555 (PAR-1 antagonist)
  - Acute coronary syndrome (ACS), Atherothrombotic disease
    - Phase II studies ongoing: two in U.S. and Europe and two in Japan
    - Target to achieve POC (proof of concept) in 1H FY2009
    - Submission target: Simultaneous NDA/MAA submissions for ACS in Japan, U.S. and Europe in FY2012
- MORAb-003 (farletuzumab, target folate receptor alpha)
  - Ovarian cancer
    - Completed enrollment of Phase II studies and started preparation for Phase III studies
    - Received orphan drug status from European Commission in April 2008
    - Submission target: U.S. NDA submission in FY2012

- AS-3201 (Diabetic neuropathy)
  - Finalizing development strategy based on meeting with FDA about Phase II results
    - Motor nerve conduction velocity (MNCV) to be used as the primary endpoint and clinical score to be used as secondary endpoint
    - Phase II/III to start in FY2008
    - Submission target: NDA/MAA submission in FY2012

Forecast to Launch 13 NME/13 LCM from FY2008 to FY2011



New Indications/New Formulations of *Aricept*® and *AcipHex*®/*Pariet*® Aim to Further Increase Patients' Benefits

- *Aricept*®
  - Transdermal patch formulation
    - Target to develop once or twice a week formulation while maintaining the level of blood concentration of the drug when orally administered once a day
    - Target to commence Phase III study in 3Q FY2008
    - Target U.S. NDA submission in FY2009
  - Sustained release formulation
    - Goal is to improve efficacy by increasing AUC without sacrificing safety profile
    - Phase III studies ongoing in 182 sites
      Phase III studies to be completed by the end of FY2008
    - Target U.S. NDA submission in FY2009
  - Pediatric patients
    - Cognitive impairment due to Down's syndrome (Phase II ongoing)
      Cognitive impairment due to brain cancer chemotherapy (Phase III in preparation)
    - Target U.S./EU submission in FY2009
- *AcipHex*®/*Pariet*®
  - Extended release formulation (ER)
    - AcipHex ER significantly prolonged pH maintenance period (higher than pH 4) compared over esomeprazole in PK/PD study
    - Started patient enrollment for three Phase III studies (GERD, non-erosive GERD, maintenance therapy for GERD)
    - Target U.S. NDA submission in FY2009
  - Non-erosive gastroesophageal reflux disease (GERD)
    - Target sNDA resubmission in Japan in FY2008
  - Triple pack combining *Pariet*® with two other drugs for use in the eradication of *h pylori*
    - Target NDA submission in Japan in FY2009

	Composition Patent Expiry					
U.S.	November, 2010	Cognitive impairment due to Down's syndrome and chemotherapy FY2009 NDA filing 6-month extension of exclusivity	Phase III study ongoing FY2009 NDA filing 3-year data protection	Phase I study ongoing FY2009 NDA filing 3-year data protection	-	-
Japan	June, 2011	-	-	Phase I study in preparation		Phase II study ongoing FY2011 sNDA filing
	February, 2012					-

III. Return to Shareholders

Continuous and Active Return to Shareholders

Maintain dividend policy with a focus on DOE
Sustain target dividend for FY2011



IV. Prospect of Achieving the Dramatic Leap Plan (DLP) and Growth Strategy Beyond DLP

Expanding Japan Business


DRAMATIC
LEAP PLAN
2011

Scenario for Next Medium-term Strategic Plan from FY2012 to FY2016

Even though Aricept® sales will decline after composition patent expiration (FY2010 in U.S. , FY2011 in Japan and FY2012 in Europe), we still expect steady increase in sales and profits every year from new in-house products, licensed in products and new indications/formulations that will compensate for the loss

Plan to launch first-in-class/best-in-class products consecutively in growing therapeutic markets including oncology, neurodegenerative disease, and anti-

Swiftly bring new product to patients with Eisai's unique competitive advantage in each therapeutic area and enhance earning structure through independent marketing

CAGR* for overseas sales is expected to grow by double digits through implementing strategies that will meet the needs of each area in developed and emerging markets.

Enriched Clinical Projects that Support Next Medium-term Strategic Plan from FY2012 to FY2016
Aspiring to Become the Top Ten Oncology House

Submission schedule (FY2008-2011)

E7389 Breast cancer (microtubule growth suppressor)
E5564 Severe sepsis
Aricept® Transdermal patch
Sustained release
Pediatric usage
Dementia with Lewy-bodies
Pariet® /AcipHex®
Extended release
Non-erosive GERD
Triple pack for *h pylori* eradication
Humira® Crohn's disease
Clevudine Hepatitis B
E2007 Neuropathic pain
E2012 Alzheimer's disease
Lunesta® Insomnia
Saforis

Submission schedule (FY2012-2016)

E2007 Epilepsy, Migraine prophylaxis, Multiple sclerosis
E5555 Acute coronary syndrome, Atherothrombotic disease
MORAb-003 Antibody, ovarian cancer
AS-3201 Diabetic complications
E6201 Psoriasis
E7080 VEGF receptor TK inhibitor
Amolimogene Therapeutic DNA vaccine
MORAb-009 Antibody, pancreatic cancer
AKR-501 Thrombocytopenia
E3710 Acid-related disease/new PPI
E7389 Non-small cell lung cancer (microtubule growth suppressor)
E7820 Alpha-2 expression integrin inhibitor
E7974 Tubulin polymerization inhibitor
E3210 IBS
E7107 RNA splicing modulator
Irofulven Prostate cancer
ZYC300 Therapeutic DNA vaccine
E6201 Novel natural product-inspired MEK-1/MEKK-1 kinase inhibitor
E2508 Depression
E2110 Overactive bladder
BAN2401 Alzheimer's disease (anti beta amyloid)
GPI21016 Cancer therapy, radiotherapy sensitizer
GCP2 Inhibitor Chemotherapy induced neuropathy

Continuous Growth through Leveraging Regional Characteristics



Continuous Enhancement of Corporate Value

Invest in growth opportunities globally
to realize *hhc* concept
and
continuously create value for
patients, shareholders and employees
to enhance corporate value